Skip to main content

Table 3 P-values for PFS, LRR, MFS, and OS for patients with these variants vs. without

From: Germline genetic biomarkers to stratify patients for personalized radiation treatment

Variant

PFS

LRR

MFS

OS

TSC2

0.216

0.018

0.702

0.685

HLA-A V91Ma

0.402

0.173

0.769

0.757

HLA-A R68Ka

FANCD2

0.039

0.774

0.018

0.448

IFIT2

0.163

0.127

0.852

0.202

GEN1

0.164

0.154

0.750

0.138

NCOR2

0.712

0.564

0.660

0.503

TET2

0.067*

0.306

0.266

0.495

MKI67

0.025

0.480

0.151

0.195

FANCI

0.189

0.910

0.376

0.687

RAD51D

0.590

0.654

0.807

0.280

IL10RA

0.340

0.084

0.600

0.972

IDH1

0.861

0.607

0.831

0.257

HLA-F N353L

0.266

0.901

0.046

0.262

FANCA V6Db

0.157

0.270

0.722

0.839

FANCA 5c

0.346

0.623

0.244

0.070

HLA-B Y140F

0.043

0.283

0.165

0.123

HLA-DMA/B 5d

0.456

0.041

0.966

0.213

DYNC2H1 Q304L

0.531

0.773

0.245

0.120

DYNC2H1 N1576K

0.231

0.511

0.926

0.243

PPP1R15A

0.008

0.028

0.191

0.255

SLX4

0.100

0.195

0.219

0.552

HLA-DQA2

0.507

0.308

0.662

0.887

  1. P-values with bold text are < 0.05 with the variant conferring improved outcomes, those with underline text are associated with worse outcomes, and those marked with an asterisk are approaching significance
  2. aThese two variants appear together in the same group of patients
  3. bOverlap with patients with MC1R R160W
  4. cGroup of patients with the same 5 changes in FANCA
  5. d5 HLA mutations present in the same group (HLA-DMB S71N, D49V, T28A and HLA-DMA R210H, G181A)